Telix Pharmaceuticals Ltd. has published its Annual Report 2025, covering operations and financial position for the year ended December 31, 2025. The company reported continued growth in its precision medicine business, supported by the acquisition of RLS Radiopharmacies and the U.S. launch of Gozellix following FDA approval and reimbursement. Telix highlighted progress across its pipeline, including multiple active therapeutic pivotal trials in prostate, kidney and brain cancer, as well as ongoing work to address U.S. regulatory complete response letters for its investigational imaging candidates TLX250-Px (Zircaix) and TLX101-Px (Pixclara). The report also outlined ongoing investment in manufacturing and supply chain infrastructure, including facility milestones in Belgium, Japan and Australia, and noted the introduction of the company’s first sustainability report aligned with Australian climate-related disclosure requirements. The full report can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on February 20, 2026, and is solely responsible for the information contained therein.